JP2017521371A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017521371A5 JP2017521371A5 JP2016569722A JP2016569722A JP2017521371A5 JP 2017521371 A5 JP2017521371 A5 JP 2017521371A5 JP 2016569722 A JP2016569722 A JP 2016569722A JP 2016569722 A JP2016569722 A JP 2016569722A JP 2017521371 A5 JP2017521371 A5 JP 2017521371A5
- Authority
- JP
- Japan
- Prior art keywords
- ndc
- moiety
- drug
- spacer
- enzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940079593 drug Drugs 0.000 claims 31
- 239000003814 drug Substances 0.000 claims 31
- 102000004190 Enzymes Human genes 0.000 claims 19
- 108090000790 Enzymes Proteins 0.000 claims 19
- 239000002105 nanoparticle Substances 0.000 claims 19
- 125000005647 linker group Chemical group 0.000 claims 18
- 125000006850 spacer group Chemical group 0.000 claims 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 239000002202 Polyethylene glycol Substances 0.000 claims 9
- 229920001223 polyethylene glycol Polymers 0.000 claims 9
- 102000035195 Peptidases Human genes 0.000 claims 7
- 108091005804 Peptidases Proteins 0.000 claims 7
- 239000004365 Protease Substances 0.000 claims 7
- 235000001014 amino acid Nutrition 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 6
- 239000007850 fluorescent dye Substances 0.000 claims 6
- 230000008685 targeting Effects 0.000 claims 6
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 4
- 108010016626 Dipeptides Proteins 0.000 claims 4
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 4
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 4
- 229960002448 dasatinib Drugs 0.000 claims 4
- 229960002584 gefitinib Drugs 0.000 claims 4
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 230000002285 radioactive effect Effects 0.000 claims 4
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 claims 4
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims 4
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims 4
- 229920000620 organic polymer Polymers 0.000 claims 3
- ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 claims 2
- CLUOUYPICNCYNF-IPIKRLCPSA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;(2s)-2-amino-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CCCNC(N)=N.OC(=O)[C@@H](N)CC1=CC=CC=C1 CLUOUYPICNCYNF-IPIKRLCPSA-N 0.000 claims 2
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 claims 2
- 102000004225 Cathepsin B Human genes 0.000 claims 2
- 108090000712 Cathepsin B Proteins 0.000 claims 2
- 102000005927 Cysteine Proteases Human genes 0.000 claims 2
- 108010005843 Cysteine Proteases Proteins 0.000 claims 2
- 102000012479 Serine Proteases Human genes 0.000 claims 2
- 108010022999 Serine Proteases Proteins 0.000 claims 2
- 102000004142 Trypsin Human genes 0.000 claims 2
- 108090000631 Trypsin Proteins 0.000 claims 2
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000007062 hydrolysis Effects 0.000 claims 2
- 238000006460 hydrolysis reaction Methods 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 239000000377 silicon dioxide Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 239000012588 trypsin Substances 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 1
- 230000001588 bifunctional effect Effects 0.000 claims 1
- 125000003827 glycol group Chemical group 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462004738P | 2014-05-29 | 2014-05-29 | |
| US62/004,738 | 2014-05-29 | ||
| US201462094923P | 2014-12-19 | 2014-12-19 | |
| US62/094,923 | 2014-12-19 | ||
| PCT/US2015/032565 WO2015183882A1 (en) | 2014-05-29 | 2015-05-27 | Nanoparticle drug conjugates |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017521371A JP2017521371A (ja) | 2017-08-03 |
| JP2017521371A5 true JP2017521371A5 (enExample) | 2019-01-10 |
| JP6573633B2 JP6573633B2 (ja) | 2019-09-11 |
Family
ID=53284649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016569722A Active JP6573633B2 (ja) | 2014-05-29 | 2015-05-27 | ナノ粒子薬物コンジュゲート |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10111963B2 (enExample) |
| EP (2) | EP3148591B1 (enExample) |
| JP (1) | JP6573633B2 (enExample) |
| KR (2) | KR102051038B1 (enExample) |
| CN (2) | CN106659797B (enExample) |
| AU (1) | AU2015267200B2 (enExample) |
| BR (1) | BR112016027624A8 (enExample) |
| CA (2) | CA3201974C (enExample) |
| DK (1) | DK3148591T3 (enExample) |
| ES (1) | ES2788865T3 (enExample) |
| PL (1) | PL3148591T3 (enExample) |
| RU (1) | RU2016144055A (enExample) |
| WO (1) | WO2015183882A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2639310T3 (es) | 2009-07-02 | 2017-10-26 | Sloan-Kettering Institute For Cancer Research | Nanopartículas fluorescentes basadas en sílice |
| US12161734B2 (en) | 2009-07-02 | 2024-12-10 | Sloan-Kettering Institute For Cancer Research | Multimodal silica-based nanoparticles |
| AU2014232907B2 (en) | 2013-03-15 | 2017-12-21 | Cornell University | Multimodal silica-based nanoparticles |
| RU2016127260A (ru) | 2013-12-31 | 2018-02-06 | Мемориал Слоун Кеттеринг Кэнсэ Сентр | Системы, способы и устройство для многоканального отображения флюоресцентных источников в режиме реального времени |
| US10111963B2 (en) | 2014-05-29 | 2018-10-30 | Memorial Sloan Kettering Cancer Center | Nanoparticle drug conjugates |
| RU2017122621A (ru) | 2014-12-15 | 2019-01-17 | Мемориал Слоун Кеттеринг Кэнсер Сентр | Циклические пептиды с улучшенной селективностью связывания с нервами, наночастицы, связанные с указанными циклическими пептидами, и их применение для визуализации нервной ткани in vivo в реальном времени |
| JP6974178B2 (ja) | 2015-05-29 | 2021-12-01 | メモリアル スローン ケタリング キャンサー センター | フェロトーシスを介して栄養欠乏がん細胞の細胞死を誘導するための極小ナノ粒子を使用する処置方法 |
| KR20190003630A (ko) * | 2016-04-29 | 2019-01-09 | 메모리얼 슬로안 케터링 캔서 센터 | 악성 뇌 종양에서의 표적화된 입자 침투, 분포, 및 반응을 위한 조성물 및 방법 |
| EP3481272A4 (en) | 2016-07-07 | 2020-03-11 | Memorial Sloan Kettering Cancer Center | IMAGING SYSTEMS AND METHODS FOR PARTICLE CONTROLLED, KNOWLEDGE-BASED AND PREDICTIVE CANCER RADIOGENOMICS |
| CN110869057A (zh) * | 2017-05-25 | 2020-03-06 | 纪念斯隆凯特琳癌症中心 | 用锆-89标记的超小纳米颗粒及其方法 |
| EP3642599B1 (en) | 2017-06-23 | 2025-01-08 | Memorial Sloan-Kettering Cancer Center | Method of imaging in vivo tissues using nanoparticles comprising a reference dye and a sensor dye. |
| RU2679075C1 (ru) * | 2017-11-09 | 2019-02-05 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) | Конъюгат люминесцентных наночастиц диоксида кремния с рекомбинантными однодоменными нано - моноантителами C7b ламы, способными специфически взаимодействовать с рекомбинантным белком HER2/neu - аналогом природного рецептора эпидермального фактора роста EGFR/ERBB клеток человека |
| WO2019113004A1 (en) | 2017-12-04 | 2019-06-13 | Memorial Sloan Kettering Cancer Center | Methods of cancer treatment via regulated ferroptosis |
| EP3866962A4 (en) | 2018-10-16 | 2021-11-24 | Silicycle Inc. | ADJUSTABLE PROCESS FOR MANUFACTURING SILICON DIOXIDE CAPSULES / BALLS AND THEIR USE |
| GB201904336D0 (en) * | 2019-03-28 | 2019-05-15 | Sisaf Ltd | A delivery system |
| WO2022076523A1 (en) * | 2020-10-06 | 2022-04-14 | Washington University | Methods and compositions for imaging and treating cancer |
| EP4103236B1 (en) | 2020-10-27 | 2023-08-16 | Elucida Oncology, Inc. | Folate receptor targeted nanoparticle drug conjugates and uses thereof |
| CN112168977A (zh) * | 2020-10-27 | 2021-01-05 | 西南大学 | 转铁蛋白修饰的二氧化硅荷载白藜芦醇及制备方法和应用 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3870791A (en) | 1972-04-24 | 1975-03-11 | Heskel M Haddad | Solid state ophthalmic medication delivery method |
| US3867519A (en) | 1972-04-27 | 1975-02-18 | Alza Corp | Bioerodible drug delivery device |
| US4051842A (en) | 1975-09-15 | 1977-10-04 | International Medical Corporation | Electrode and interfacing pad for electrical physiological systems |
| DE2626348C3 (de) | 1976-06-11 | 1980-01-31 | Siemens Ag, 1000 Berlin Und 8000 Muenchen | Implantierbare Dosiereinrichtung |
| US4136177A (en) | 1977-01-31 | 1979-01-23 | American Home Products Corp. | Xanthan gum therapeutic compositions |
| US4255415A (en) | 1978-11-22 | 1981-03-10 | Schering Corporation | Polyvinyl alcohol ophthalmic gel |
| US4383529A (en) | 1980-11-03 | 1983-05-17 | Wescor, Inc. | Iontophoretic electrode device, method and gel insert |
| US4931279A (en) | 1985-08-16 | 1990-06-05 | Bausch & Lomb Incorporated | Sustained release formulation containing an ion-exchange resin |
| US4688506A (en) | 1985-09-03 | 1987-08-25 | Breems Martinus Van | Boat sail control system |
| US4788603A (en) | 1985-10-19 | 1988-11-29 | Fuji Photo Film Co., Ltd. | Camera for sequentially photographing a subject using a reference optical system and a telescopic optical system |
| US4812409A (en) | 1986-01-31 | 1989-03-14 | Eastman Kodak Company | Hydrolyzable fluorescent substrates and analytical determinations using same |
| US4713224A (en) | 1986-03-31 | 1987-12-15 | The Boc Group, Inc. | One-step process for purifying an inert gas |
| US4810636A (en) | 1986-12-09 | 1989-03-07 | Miles Inc. | Chromogenic acridinone enzyme substrates |
| US4774339A (en) | 1987-08-10 | 1988-09-27 | Molecular Probes, Inc. | Chemically reactive dipyrrometheneboron difluoride dyes |
| US5433896A (en) | 1994-05-20 | 1995-07-18 | Molecular Probes, Inc. | Dibenzopyrrometheneboron difluoride dyes |
| US5274113A (en) | 1991-11-01 | 1993-12-28 | Molecular Probes, Inc. | Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates |
| US5248782A (en) | 1990-12-18 | 1993-09-28 | Molecular Probes, Inc. | Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes |
| US5187288A (en) | 1991-05-22 | 1993-02-16 | Molecular Probes, Inc. | Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis |
| US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| US5830912A (en) | 1996-11-15 | 1998-11-03 | Molecular Probes, Inc. | Derivatives of 6,8-difluoro-7-hydroxycoumarin |
| GB2330907A (en) | 1997-10-28 | 1999-05-05 | Applied Imaging Int Ltd | A karyotyper and methods for producing karyotypes |
| WO1999037814A1 (en) | 1998-01-22 | 1999-07-29 | Luminex Corporation | Microparticles with multiple fluorescent signals |
| US6254852B1 (en) | 1999-07-16 | 2001-07-03 | Dupont Pharmaceuticals Company | Porous inorganic targeted ultrasound contrast agents |
| US7279150B2 (en) | 2002-01-24 | 2007-10-09 | Barnes-Jewish Hospital | Chelating agents with lipophilic carriers |
| CA2476888A1 (en) | 2002-02-01 | 2003-08-14 | Vanderbilt University | Targeted drug delivery methods |
| US8620410B2 (en) | 2002-03-12 | 2013-12-31 | Beth Israel Deaconess Medical Center | Multi-channel medical imaging system |
| US20040101822A1 (en) | 2002-11-26 | 2004-05-27 | Ulrich Wiesner | Fluorescent silica-based nanoparticles |
| WO2004108902A2 (en) | 2003-06-04 | 2004-12-16 | Visen Medical, Inc. | Biocompatible fluorescent silicon nanoparticles |
| WO2006042233A1 (en) | 2004-10-08 | 2006-04-20 | The Cleveland Clinic Foundation | Medical imaging using quantum dots |
| US7653427B2 (en) | 2004-11-12 | 2010-01-26 | Intra-Medical Imaging LLC | Method and instrument for minimally invasive sentinel lymph node location and biopsy |
| EP1861072A2 (en) * | 2005-03-14 | 2007-12-05 | Massachusetts Institute Of Technology | Nanocells for diagnosis and treatment of diseases and disorders |
| EP1957045A2 (en) | 2005-03-14 | 2008-08-20 | Board of Regents, The University of Texas System | Bioactive fus1 peptides and nanoprticle-polypeptide complexes |
| US8084001B2 (en) | 2005-05-02 | 2011-12-27 | Cornell Research Foundation, Inc. | Photoluminescent silica-based sensors and methods of use |
| WO2007053189A2 (en) | 2005-06-01 | 2007-05-10 | Northwestern University | Compositions and methods for altering immune function |
| EP1893245A4 (en) | 2005-06-24 | 2009-06-24 | Univ Pennsylvania | RADIOMARQUE PEGYLATION OF LIGANDS FOR USE AS IMAGING AGENTS |
| FR2888753B1 (fr) | 2005-07-21 | 2008-04-04 | Commissariat Energie Atomique | Vecteur cible avec fonction d'imagerie activable |
| WO2007136413A2 (en) | 2005-12-22 | 2007-11-29 | Visen Medical, Inc. | Biocompatible fluorescent metal oxide nanoparticles |
| WO2008044138A1 (en) | 2006-10-12 | 2008-04-17 | Syddansk Universitet | Optical nanosensor for detection of reactive oxygen species |
| WO2008049118A2 (en) | 2006-10-19 | 2008-04-24 | The General Hospital Corporation | Apparatus and method for obtaining and providing imaging information associated with at least one portion of a sample and effecting such portion(s) |
| US7902332B2 (en) | 2006-11-30 | 2011-03-08 | General Electric Company | Fluorine-labeled compounds |
| AU2007333225B2 (en) | 2006-12-08 | 2014-06-12 | Massachusetts Institute Of Technology | Delivery of nanoparticles and/or agents to cells |
| US20080255425A1 (en) | 2007-04-13 | 2008-10-16 | Ethicon Endo-Surgery, Inc. | Nanoparticle treated medical devices |
| EP1995327A1 (en) | 2007-05-21 | 2008-11-26 | Humboldt Universität zu Berlin | Probe for detecting a particular nucleic acid sequence |
| WO2009029870A2 (en) | 2007-08-31 | 2009-03-05 | Hybrid Silica Technologies, Inc. | Peg-coated core-shell silica nanoparticles and methods of manufacture and use |
| DE102007052517A1 (de) | 2007-10-29 | 2009-04-30 | Autoimmun Diagnostika Gmbh | ELISPOT-Verfahren mit zwei Filtersystemen |
| WO2009064964A2 (en) | 2007-11-15 | 2009-05-22 | The University Of California | Switchable nano-vehicle delivery systems, and methods for making and using them |
| JP5526036B2 (ja) | 2007-12-21 | 2014-06-18 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 三次元の回折限界未満の画像解像技術 |
| WO2010091294A2 (en) | 2009-02-05 | 2010-08-12 | The Regents Of The University Of California | New targeted antimicrobial moieties |
| ES2639310T3 (es) | 2009-07-02 | 2017-10-26 | Sloan-Kettering Institute For Cancer Research | Nanopartículas fluorescentes basadas en sílice |
| EP2512522A4 (en) * | 2009-12-16 | 2013-09-25 | Brigham & Womens Hospital | PARTICLES FOR ADMINISTRATION OF MULTIPLE AGENTS |
| RS52983B (sr) * | 2010-04-15 | 2014-02-28 | Spirogen Sárl | Pirolobenzodiazepini i njihovi konjugati |
| WO2013192609A1 (en) * | 2012-06-22 | 2013-12-27 | Cornell University | Mesoporous oxide nanoparticles and methods of making and using same |
| US9695133B2 (en) | 2012-07-13 | 2017-07-04 | The Trustees Of Columbia University In The City Of New York | Quinazolinone-based oncogenic-RAS-selective lethal compounds and their use |
| CN112587658A (zh) * | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| AU2014232907B2 (en) | 2013-03-15 | 2017-12-21 | Cornell University | Multimodal silica-based nanoparticles |
| US10111963B2 (en) | 2014-05-29 | 2018-10-30 | Memorial Sloan Kettering Cancer Center | Nanoparticle drug conjugates |
| JP6974178B2 (ja) | 2015-05-29 | 2021-12-01 | メモリアル スローン ケタリング キャンサー センター | フェロトーシスを介して栄養欠乏がん細胞の細胞死を誘導するための極小ナノ粒子を使用する処置方法 |
| EP3642599B1 (en) | 2017-06-23 | 2025-01-08 | Memorial Sloan-Kettering Cancer Center | Method of imaging in vivo tissues using nanoparticles comprising a reference dye and a sensor dye. |
-
2015
- 2015-05-27 US US14/722,307 patent/US10111963B2/en active Active
- 2015-05-27 ES ES15727248T patent/ES2788865T3/es active Active
- 2015-05-27 DK DK15727248.5T patent/DK3148591T3/da active
- 2015-05-27 KR KR1020167035356A patent/KR102051038B1/ko active Active
- 2015-05-27 BR BR112016027624A patent/BR112016027624A8/pt active Search and Examination
- 2015-05-27 CN CN201580029280.1A patent/CN106659797B/zh active Active
- 2015-05-27 CA CA3201974A patent/CA3201974C/en active Active
- 2015-05-27 JP JP2016569722A patent/JP6573633B2/ja active Active
- 2015-05-27 PL PL15727248T patent/PL3148591T3/pl unknown
- 2015-05-27 RU RU2016144055A patent/RU2016144055A/ru not_active Application Discontinuation
- 2015-05-27 WO PCT/US2015/032565 patent/WO2015183882A1/en not_active Ceased
- 2015-05-27 CN CN202110399761.9A patent/CN113082225A/zh active Pending
- 2015-05-27 EP EP15727248.5A patent/EP3148591B1/en active Active
- 2015-05-27 KR KR1020197034930A patent/KR102231672B1/ko active Active
- 2015-05-27 EP EP20152240.6A patent/EP3693026A1/en active Pending
- 2015-05-27 AU AU2015267200A patent/AU2015267200B2/en active Active
- 2015-05-27 CA CA2947895A patent/CA2947895C/en active Active
-
2018
- 2018-09-21 US US16/137,709 patent/US10485881B2/en active Active
-
2019
- 2019-10-15 US US16/653,490 patent/US20200289668A1/en not_active Abandoned
-
2024
- 2024-10-10 US US18/911,705 patent/US20250269054A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017521371A5 (enExample) | ||
| Chavda et al. | Peptide-drug conjugates: a new hope for cancer management | |
| Dheer et al. | Cathepsin-sensitive nanoscale drug delivery systems for cancer therapy and other diseases | |
| Sapra et al. | Designer peptide and protein dendrimers: a cross-sectional analysis | |
| Veronese et al. | PEG− doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity | |
| Chang et al. | Smart linkers in polymer–drug conjugates for tumor-targeted delivery | |
| Hu et al. | Advances in peptide functionalization on mesoporous silica nanoparticles for controlled drug release | |
| ES2383901T3 (es) | Polipéptidos de aprotinina para transportar un compuesto a través de la barrera sangre-cerebro | |
| Garsky et al. | The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy | |
| KR102051038B1 (ko) | 나노입자 약물 컨쥬게이트 | |
| Zhang et al. | Enhanced cellular entry and efficacy of tat conjugates by rational design of the auxiliary segment | |
| Böhme et al. | Drug delivery and release systems for targeted tumor therapy | |
| US9216228B2 (en) | Receptor and antigen targeted prodrug | |
| Brady et al. | Design and synthesis of a pro-drug of vinblastine targeted at treatment of prostate cancer with enhanced efficacy and reduced systemic toxicity | |
| ES2269160T3 (es) | Procedimiento para la preparacion de una formulacion medicamentosa inyectable. | |
| ES2269397T3 (es) | Sistemas de ligando terapeuticos y de diagnostico que comprenden propiedades de union a moleculas de transporte y medicamentos que los contienen. | |
| Fernandez et al. | N-Succinyl-(β-alanyl-l-leucyl-l-alanyl-l-leucyl) doxorubicin: an extracellularly tumor-activated prodrug devoid of intravenous acute toxicity | |
| Fominaya et al. | Strategies to stabilize cell penetrating peptides for in vivo applications | |
| JP2009500431A5 (enExample) | ||
| CN103402545A (zh) | 疏水性经修饰肽及其在肝特异性靶向中的用途 | |
| CN106573031A (zh) | 双末端聚乙二醇化整合素‑结合肽及其使用方法 | |
| CN103080125A (zh) | 用于治疗性结合物的短且含d氨基酸的多肽及其使用 | |
| WO2019061561A1 (zh) | 一种药物递送体系及其制备方法与应用 | |
| Wang et al. | Peptide-mediated nanocarriers for targeted drug delivery: Developments and strategies | |
| JP2012521201A5 (enExample) |